Dashboard
1
The company has declared Positive results for the last 10 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at CNY 2,163.79 MM
- NET PROFIT(HY) At CNY 1,187.76 MM has Grown at 59.72%
- ROCE(HY) Highest at 34.9%
2
With ROE of 29.16%, it has a attractive valuation with a 7.88 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 36,153 Million (Large Cap)
15.00
NA
0.00%
-0.41
30.78%
4.67
Revenue and Profits:
Net Sales:
1,584 Million
(Quarterly Results - Mar 2026)
Net Profit:
636 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
2.07%
0%
2.07%
6 Months
-14.26%
0%
-14.26%
1 Year
0.45%
0%
0.45%
2 Years
45.25%
0%
45.25%
3 Years
263.7%
0%
263.7%
4 Years
293.72%
0%
293.72%
5 Years
226.93%
0%
226.93%
Shanghai Allist Pharmaceuticals Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
173.97%
EBIT Growth (5y)
58.36%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.65
Sales to Capital Employed (avg)
0.66
Tax Ratio
13.82%
Dividend Payout Ratio
20.56%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
27.87%
ROE (avg)
10.46%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
4.67
EV to EBIT
12.84
EV to EBITDA
12.68
EV to Capital Employed
7.19
EV to Sales
5.82
PEG Ratio
0.26
Dividend Yield
NA
ROCE (Latest)
56.00%
ROE (Latest)
30.78%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
1,583.80
1,454.30
8.90%
Operating Profit (PBDIT) excl Other Income
721.10
648.60
11.18%
Interest
0.00
0.00
Exceptional Items
7.00
8.30
-15.66%
Consolidate Net Profit
636.00
573.30
10.94%
Operating Profit Margin (Excl OI)
455.30%
437.90%
1.74%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 8.90% vs 6.99% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 10.94% vs 1.56% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
5,123.80
3,516.00
45.73%
Operating Profit (PBDIT) excl Other Income
2,339.60
1,515.00
54.43%
Interest
0.20
0.10
100.00%
Exceptional Items
40.30
28.90
39.45%
Consolidate Net Profit
2,189.10
1,429.80
53.11%
Operating Profit Margin (Excl OI)
447.90%
419.60%
2.83%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 45.73% vs 76.54% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 53.11% vs 121.95% in Dec 2024
About Shanghai Allist Pharmaceuticals Co., Ltd. 
Shanghai Allist Pharmaceuticals Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






